Arthneeti
SP

SMS Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Q3 FY26: Revenue ₹210.45 Cr, PAT ₹23.47 Cr

Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹474
Market cap₹4.1K Cr
P/E40.5
Updated25 Sept 2026
Read3 min read

Based on SMS Pharmaceuticals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p

From SMS Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27]
  • Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27]
  • Q3FY26 PAT after MI & Associate: ₹23.47 crore, up 29% YoY [Page 27]
  • EPS for Q3FY26: ₹2.59, up 20% YoY [Page 27, 6]
  • Volume growth noted as a key driver for revenue increase; strong volume growth in key APIs highlighted [Page 5]

2 more points management made on revenue & sales performance

Profitability & Margins

See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).
  • Capex oriented towards:
  • Capacity expansion for existing APIs.
  • Building capacities for a new API pipeline.
  • Land acquisition underway for a greenfield project (Page 25).
  • Capex project mix: 89% brownfield (capacity expansion), 11% greenfield (new plant) (Page 25).
  • Strategic focus post last 3-4 years' capex cycle is on asset utilization to deliver high-teen returns (Page 25).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided investor presentation does not explicitly mention or report any details regarding: - Order book - Order inflow - Pending orders No specific figures or commentary related to current or future orders, order backlog, or order inflow are included in the document. The presentation primarily focuses on financial performance, operational highlights, strategic outlook, product portfolio, customer base, and manufacturing capabilities without detailing order metrics.

SMS Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences Ltd (Q3 FY26)

    180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • Morepen Laboratories Ltd (Q3 FY26)

    488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • Jubilant Pharmova Ltd (Q3 FY26)

    2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q3 FY26)

    Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key concall takeaways from NGL Fine Chem Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were SMS Pharmaceuticals Ltd Q3 FY26 results?

Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p

What is SMS Pharmaceuticals Ltd share price analysis?

SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.

Is SMS Pharmaceuticals Ltd planning capital expenditure?

Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).

Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.